checkAd

Bolt Biotherapeutics Announces AACR 2021 Presentation of Boltbody Platform Mechanism of Action and Clinical Properties of Lead ISAC, BDC-1001

Nachrichtenquelle: globenewswire
10.04.2021, 14:30  |  132   |   |   

Bolt’s first-in-class clinical candidate, BDC-1001, is a novel HER2-targeting, TLR 7/8 immune-stimulating antibody conjugate (ISAC) currently in an ongoing Phase 1/2 first-in-human study

REDWOOD CITY, Calif., April 10, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today announced that an online oral presentation with live Q&A and a Trial in Progress poster presentation for lead agent BDC-1001 are being presented at the American Association for Cancer Research (AACR) Annual Meeting 2021 being held virtually from April 10-15th.

The oral presentation explores immunosuppression mediated by various cells in the tumor microenvironment (TME), as well as the tumor-supportive nature of antigen presenting cells (APCs) in the TME in preclinical models. Reawakening these immunosuppressed APCs may result in a productive and durable anti-tumor immune response. Bolt is utilizing its Boltbody platform to create immune-stimulating antibody conjugates (ISACs), such as BDC-1001, that invoke this mechanism and provided complete tumor regression in preclinical tumor models.

“In murine models we have seen efficacy in a variety of tumors that are immunologically cold and well-established. Furthermore, consistent with our proposed mechanism of action for ISACs, we see evidence of increased myeloid and T cell infiltration in the tumor microenvironment mediated by BDC-1001 surrogate ISACs,” said David Dornan, Ph.D., Chief Scientific Officer at Bolt Biotherapeutics. “We’re excited to share our rationale for selecting the linker-payload for BDC-1001 to optimize anti-tumor activity while minimizing the potential for the formation of anti-drug antibodies.”

BDC-1001 is comprised of a tumor antigen-targeting monoclonal antibody (mAb), a trastuzumab biosimilar and an immune-stimulating agent (a TLR7/8 agonist) conjugated to each other with a non-cleavable linker. In a series of preclinical studies with BDC-1001, Bolt demonstrated the mechanism of action for their HER2-targeted ISAC. BDC-1001 surrogate was able to eliminate established, treatment-resistant tumors through the engagement of both innate and adaptive immunity. There were no adverse findings in toxicology studies of BDC-1001.

Seite 1 von 5
Bolt Biotherapeutics Aktie jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf Smartbroker.de





0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Bolt Biotherapeutics Announces AACR 2021 Presentation of Boltbody Platform Mechanism of Action and Clinical Properties of Lead ISAC, BDC-1001 Bolt’s first-in-class clinical candidate, BDC-1001, is a novel HER2-targeting, TLR 7/8 immune-stimulating antibody conjugate (ISAC) currently in an ongoing Phase 1/2 first-in-human studyREDWOOD CITY, Calif., April 10, 2021 (GLOBE NEWSWIRE) - Bolt …

Nachrichten des Autors

Titel
Titel
Titel
Titel